首页 > 最新文献

Indian Journal of Gastroenterology最新文献

英文 中文
Renal dysfunction in routine proton-pump inhibitor use may be linked to comorbidities: A real-world observational study. 常规使用质子泵抑制剂的肾功能障碍可能与合并症有关:一项真实世界观察研究。
IF 2 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-02-26 DOI: 10.1007/s12664-023-01515-9
Adeshkumar Andhale, Philip Abraham, Pavan Dhoble, Devendra Desai, Anand Joshi, Tarun Gupta, Jatin Kothari, Nikhil Bhangale

Introduction: The use of proton-pump inhibitors (PPI) is linked with infrequent but serious adverse events, including acute kidney injury, chronic kidney disease (CKD) and progression of CKD. Data on renal safety in routine use of PPI are more relevant to clinical practice. We studied whether such use of PPI is associated with renal dysfunction.

Methods: Patients taking PPI for at least six weeks had serum creatinine tested pre (n = 200) and post (n = 180) recruitment. These patients were then advised to follow-up: those taking PPI for at least 90 days in the next six months (n = 77) and at least another 90 days in the following six months (n = 50), had serum creatinine tested at such follow-up. Renal dysfunction was defined as any increase in serum creatinine level above baseline.

Results: The 200 patients recruited had mean age 39.6 (SD 9.2) years. Ninety-eight (49%) patients had a history of previous PPI use (median six months; interquartile range [IQR] 3-24). Only 20 (11.1%) patients at six weeks, 11 (14.3%) at six months and six (12%) at one year had increase in creatinine level; a majority of them had less than 0.3 mg/dL increase. Ten of these 20 (six weeks), five of 11 (six months) and five of six (one year) had other risk factors for renal dysfunction. No patient developed CKD during the study period.

Conclusions: Mild and non-progressive increase in serum creatinine occurred in 10% to 15% of patients on routine PPI use. A majority of them had other risk factors. Small sample size and short follow-up duration are a few limitations of this study.

简介:质子泵抑制剂(PPI)的使用与不常见但严重的不良事件有关,包括急性肾损伤、慢性肾病(CKD)和 CKD 的恶化。常规使用 PPI 时的肾脏安全性数据与临床实践更为相关。我们研究了使用 PPI 是否与肾功能障碍有关:方法:服用 PPI 至少六周的患者在招募前(200 人)和招募后(180 人)接受血清肌酐检测。然后建议这些患者进行随访:在接下来的六个月中至少服用 PPI 90 天的患者(77 人)和在接下来的六个月中至少再服用 PPI 90 天的患者(50 人),在随访时检测血清肌酐。肾功能障碍的定义是血清肌酐水平高于基线:招募的 200 名患者平均年龄为 39.6 岁(标准差为 9.2 岁)。98名患者(49%)曾使用过 PPI(中位数为 6 个月;四分位数间距 [IQR] 3-24)。只有 20 名(11.1%)患者在六周、11 名(14.3%)患者在六个月和 6 名(12%)患者在一年后出现肌酐水平升高;其中大多数患者的肌酐升高幅度小于 0.3 毫克/分升。这 20 人中有 10 人(6 周)、11 人中有 5 人(6 个月)和 6 人中有 5 人(1 年)有其他肾功能障碍的危险因素。在研究期间,没有患者发展为慢性肾脏病:结论:10%-15%的常规服用 PPI 的患者会出现轻度、非进行性的血清肌酐升高。他们中的大多数人都有其他风险因素。样本量小、随访时间短是这项研究的一些局限性。
{"title":"Renal dysfunction in routine proton-pump inhibitor use may be linked to comorbidities: A real-world observational study.","authors":"Adeshkumar Andhale, Philip Abraham, Pavan Dhoble, Devendra Desai, Anand Joshi, Tarun Gupta, Jatin Kothari, Nikhil Bhangale","doi":"10.1007/s12664-023-01515-9","DOIUrl":"10.1007/s12664-023-01515-9","url":null,"abstract":"<p><strong>Introduction: </strong>The use of proton-pump inhibitors (PPI) is linked with infrequent but serious adverse events, including acute kidney injury, chronic kidney disease (CKD) and progression of CKD. Data on renal safety in routine use of PPI are more relevant to clinical practice. We studied whether such use of PPI is associated with renal dysfunction.</p><p><strong>Methods: </strong>Patients taking PPI for at least six weeks had serum creatinine tested pre (n = 200) and post (n = 180) recruitment. These patients were then advised to follow-up: those taking PPI for at least 90 days in the next six months (n = 77) and at least another 90 days in the following six months (n = 50), had serum creatinine tested at such follow-up. Renal dysfunction was defined as any increase in serum creatinine level above baseline.</p><p><strong>Results: </strong>The 200 patients recruited had mean age 39.6 (SD 9.2) years. Ninety-eight (49%) patients had a history of previous PPI use (median six months; interquartile range [IQR] 3-24). Only 20 (11.1%) patients at six weeks, 11 (14.3%) at six months and six (12%) at one year had increase in creatinine level; a majority of them had less than 0.3 mg/dL increase. Ten of these 20 (six weeks), five of 11 (six months) and five of six (one year) had other risk factors for renal dysfunction. No patient developed CKD during the study period.</p><p><strong>Conclusions: </strong>Mild and non-progressive increase in serum creatinine occurred in 10% to 15% of patients on routine PPI use. A majority of them had other risk factors. Small sample size and short follow-up duration are a few limitations of this study.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of donor morbidity in 177 donor hepatectomies for living donor liver transplant: Experience from a high-volume centre in western India. 分析 177 例活体肝移植肝切除术中供体的发病率:印度西部一个高容量中心的经验。
IF 2 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-04-17 DOI: 10.1007/s12664-024-01552-y
Shailesh Sable, Vibha Varma, Sorabh Kapoor, Samriddhi Poyekar, Barun Nath, Vinay Kumaran

Background: Living donor liver transplant (LDLT) is based on the principle of double equipoise. Organ shortage in Asian countries has led to development of high-volume LDLT programs with good outcomes. Safety of live liver donor is the Achilles heel of LDLT program and every effort should be made to achieve low morbidity and near zero mortality rates.

Methods: We retrospectively analyzed our prospectively maintained donor morbidity data (outcomes) of 177 donors in a new transplant program setup in western India by an experienced surgeon. The primary end point was to analyze the morbidity rates and the factors associated with it.

Results: None of the donors in our cohort of 177 donors developed grade IV or V complication (Clavien-Dindo classification). One-fourth (1/4th) of the donors developed complications ranging from grade I to grade III(b). The rate of complications according to modified Clavien-Dindo classification is as follows: (1) grade I in 5.6% (n = 10), (2) grade II in 14.6% (n = 26), (3) grade III(a) in 3.9% (n = 7), (4) grade III(b) in 2.2% (n = 4). Three donors (1.6%) developed post-hepatectomy intra-abdominal bleeding and required re-exploration (grade IIIb). All of them recovered well post-surgery and are doing well in follow-up. The mean follow-up of the entire cohort was 2871 ± 521 days (range 1926-3736 days).

Conclusion: Donor safety (outcome) is determined by meticulous donor surgery and good-quality remnant.

背景:活体肝移植(LDLT)基于双等位原则。亚洲国家的器官短缺导致了大量 LDLT 项目的发展,并取得了良好的效果。活体肝脏捐献者的安全性是 LDLT 项目的致命弱点,因此应尽一切努力实现低发病率和接近零的死亡率:我们回顾性地分析了在印度西部由一位经验丰富的外科医生建立的新移植项目中前瞻性保存的 177 位供体的发病率数据(结果)。主要终点是分析发病率及其相关因素:结果:在我们的 177 位供体中,没有一位出现 IV 级或 V 级并发症(Clavien-Dindo 分类)。四分之一(1/4)的供体出现了从 I 级到 III(b)级的并发症。根据修改后的克拉维恩-丁多分类法,并发症发生率如下:(1)I级占5.6%(10人),(2)II级占14.6%(26人),(3)III(a)级占3.9%(7人),(4)III(b)级占2.2%(4人)。有 3 名供体(1.6%)在肝切除术后出现腹腔内出血,需要再次手术(IIIb 级)。他们术后均恢复良好,随访情况良好。整个组群的平均随访时间为 2871 ± 521 天(范围为 1926-3736 天):供体安全(结果)取决于精细的供体手术和优质的残留物。
{"title":"Analysis of donor morbidity in 177 donor hepatectomies for living donor liver transplant: Experience from a high-volume centre in western India.","authors":"Shailesh Sable, Vibha Varma, Sorabh Kapoor, Samriddhi Poyekar, Barun Nath, Vinay Kumaran","doi":"10.1007/s12664-024-01552-y","DOIUrl":"10.1007/s12664-024-01552-y","url":null,"abstract":"<p><strong>Background: </strong>Living donor liver transplant (LDLT) is based on the principle of double equipoise. Organ shortage in Asian countries has led to development of high-volume LDLT programs with good outcomes. Safety of live liver donor is the Achilles heel of LDLT program and every effort should be made to achieve low morbidity and near zero mortality rates.</p><p><strong>Methods: </strong>We retrospectively analyzed our prospectively maintained donor morbidity data (outcomes) of 177 donors in a new transplant program setup in western India by an experienced surgeon. The primary end point was to analyze the morbidity rates and the factors associated with it.</p><p><strong>Results: </strong>None of the donors in our cohort of 177 donors developed grade IV or V complication (Clavien-Dindo classification). One-fourth (1/4th) of the donors developed complications ranging from grade I to grade III(b). The rate of complications according to modified Clavien-Dindo classification is as follows: (1) grade I in 5.6% (n = 10), (2) grade II in 14.6% (n = 26), (3) grade III(a) in 3.9% (n = 7), (4) grade III(b) in 2.2% (n = 4). Three donors (1.6%) developed post-hepatectomy intra-abdominal bleeding and required re-exploration (grade IIIb). All of them recovered well post-surgery and are doing well in follow-up. The mean follow-up of the entire cohort was 2871 ± 521 days (range 1926-3736 days).</p><p><strong>Conclusion: </strong>Donor safety (outcome) is determined by meticulous donor surgery and good-quality remnant.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140869137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Celiac trunk arterial variations and their clinical implications: Role of imaging. 腹腔干动脉变异及其临床意义:成像的作用。
IF 2 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-09-07 DOI: 10.1007/s12664-024-01656-5
Pawan Kumar, Anuradha Singh, G S Triveni, S H Chandrashekhara, Shivanand Gamanagatti, Vaibhav Nichat

The awareness of anatomical variations of hepatic arteries and celiac trunk is very important in interventional radiology, liver transplant and intra-abdominal oncologic surgeries. Radiology plays an important role in the identification of these variants non-invasively. Digital subtraction angiography was the gold standard for their identification. Computed tomography (CT) angiography non-invasively provides detailed knowledge of various anatomical vascular variations. This pictorial review highlights the role of multidetector computed tomography (MDCT) in the identification of celiac trunk-hepatic arterial system variations and clinical consequences.

对肝动脉和腹腔干解剖变异的认识在介入放射学、肝移植和腹腔内肿瘤手术中非常重要。放射学在无创识别这些变异方面发挥着重要作用。数字减影血管造影术是识别这些变异的金标准。计算机断层扫描(CT)血管造影术可无创地详细了解各种解剖血管变异。本图解综述强调了多载体计算机断层扫描(MDCT)在识别腹腔干-肝动脉系统变异和临床后果方面的作用。
{"title":"Celiac trunk arterial variations and their clinical implications: Role of imaging.","authors":"Pawan Kumar, Anuradha Singh, G S Triveni, S H Chandrashekhara, Shivanand Gamanagatti, Vaibhav Nichat","doi":"10.1007/s12664-024-01656-5","DOIUrl":"10.1007/s12664-024-01656-5","url":null,"abstract":"<p><p>The awareness of anatomical variations of hepatic arteries and celiac trunk is very important in interventional radiology, liver transplant and intra-abdominal oncologic surgeries. Radiology plays an important role in the identification of these variants non-invasively. Digital subtraction angiography was the gold standard for their identification. Computed tomography (CT) angiography non-invasively provides detailed knowledge of various anatomical vascular variations. This pictorial review highlights the role of multidetector computed tomography (MDCT) in the identification of celiac trunk-hepatic arterial system variations and clinical consequences.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abbreviated magnetic resonance imaging in hepatocellular carcinoma surveillance: A review. 简略磁共振成像在肝细胞癌监测中的应用:综述。
IF 2 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-03-09 DOI: 10.1007/s12664-023-01511-z
Rajath Ramegowda, Pankaj Gupta

Hepatocellular carcinoma (HCC) is one of the most common primary malignancies of the liver and a leading cause for cancer-related deaths worldwide. HCC surveillance aims at early detection. The recommended strategy for screening HCC is biannual ultrasound with or without alpha-fetoprotein. However, this strategy is associated with sub-optimal sensitivity. Abbreviated magnetic resonance imaging (AMRI) is a promising alternative to ultrasound (US) for surveillance of HCC. The data regarding the role of AMRI in HCC screening is evolving. There are different AMRI protocols, each having its merits and disadvantages. In this review, we discuss the need for AMRI, protocols of AMRI and hindrances to widespread adoption of AMRI.

肝细胞癌(HCC)是最常见的肝脏原发性恶性肿瘤之一,也是全球癌症相关死亡的主要原因。监测 HCC 的目的是及早发现。筛查 HCC 的推荐策略是每半年进行一次超声波检查,同时进行或不进行甲胎蛋白检查。然而,这种策略的灵敏度不够理想。简略磁共振成像(AMRI)是超声波(US)监测 HCC 的一种很有前途的替代方法。有关 AMRI 在 HCC 筛查中的作用的数据正在不断发展。目前有不同的 AMRI 方案,各有利弊。在这篇综述中,我们将讨论 AMRI 的必要性、AMRI 的方案以及广泛采用 AMRI 的障碍。
{"title":"Abbreviated magnetic resonance imaging in hepatocellular carcinoma surveillance: A review.","authors":"Rajath Ramegowda, Pankaj Gupta","doi":"10.1007/s12664-023-01511-z","DOIUrl":"10.1007/s12664-023-01511-z","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is one of the most common primary malignancies of the liver and a leading cause for cancer-related deaths worldwide. HCC surveillance aims at early detection. The recommended strategy for screening HCC is biannual ultrasound with or without alpha-fetoprotein. However, this strategy is associated with sub-optimal sensitivity. Abbreviated magnetic resonance imaging (AMRI) is a promising alternative to ultrasound (US) for surveillance of HCC. The data regarding the role of AMRI in HCC screening is evolving. There are different AMRI protocols, each having its merits and disadvantages. In this review, we discuss the need for AMRI, protocols of AMRI and hindrances to widespread adoption of AMRI.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140068299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discrimination of pediatric cryptogenic multifocal ulcerous stenosing enteritis from small bowel Crohn's disease and gastrointestinal tuberculosis: A retrospective study (with videos). 小儿隐源性多灶性溃疡性狭窄肠炎与小肠克罗恩病和胃肠结核的鉴别:回顾性研究(附视频)。
IF 2 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-21 DOI: 10.1007/s12664-024-01604-3
Arghya Samanta, Moinak Sen Sarma, Sumit Kumar Singh, Anshu Srivastava, Ujjal Poddar, Ankur Mandelia, Vinita Agrawal, Surendra Kumar Yachha, Richa Lal

Introduction: Cryptogenic multifocal ulcerous stenosing enteritis (CMUSE) is a rare entity that mimics various inflammatory strictures of the small intestine. Pediatric literature is scarce. We analyzed the clinical, radiological, endoscopic and histopathological features of children with CMUSE that differentiate it from small bowel Crohn's disease (SBCD) and gastrointestinal tuberculosis (GITB).

Methods: CMUSE was diagnosed by the following criteria: (1) unexplained small bowel strictures with superficial ulcers, (2) chronic/relapsing ulcers of small bowel after resection, (3) no signs of systemic inflammation, (4) absence of other known etiologies of small bowel ulcers. SBCD and GITB were diagnosed based on standard criteria. The clinical features, laboratory parameters, radioimaging, endoscopy (including video capsule endoscopy [VCE], intra-operative endoscopy), histopathological features and treatment outcome were noted.

Results: Out of 48, CMUSE was diagnosed in 13 (27%) isolated small bowel and ileocecal strictures, while GITB and SBCD accounted for 41% and 21% cases, respectively. Common presentations were sub-acute obstruction (46%), obscure gastrointestinal bleeding (38%) and protein-losing enteropathy (38%). CMUSE patients had significantly longer disease duration compared to SBCD and GITB (p < 0.001). SBCD (90.0%) and GITB (85%) cases had elevated C-reactive protein (CRP), none with CMUSE had elevated CRP (p < 0.001). The disease was localized in jejunum (100%) and proximal ileum (56%) in CMUSE, ileocecal region (85%) in GITB, but evenly distributed in small intestine in SBCD. Endoscopy showed evenly placed, superficial, circumferential ulcers with strictures in CMUSE, deep linear ulcers in SBCD and circumferential ulcers in GITB. Upfront immunosuppression was given in four; three (75%) of them relapsed. Only surgery was done in three with one (25%) having relapse. Upfront surgery followed by immunosuppression was used in six, but all relapsed and two required repeat surgery.

Conclusion: CMUSE is important but underdiagnosed in children. Lack of constitutional symptoms, normal inflammatory parameters and characteristic ulcers with strictures helped in differentiating CMUSE from GITB and SBCD.

简介隐源性多灶性溃疡性狭窄肠炎(CMUSE)是一种罕见的疾病,它模仿各种小肠炎症性狭窄。儿科文献很少。我们分析了 CMUSE 患儿的临床、放射学、内窥镜和组织病理学特征,以将其与小肠克罗恩病(SBCD)和胃肠结核(GITB)区分开来:CMUSE 的诊断标准如下:(方法:CMUSE 的诊断标准如下:(1)原因不明的小肠狭窄并伴有浅表溃疡;(2)小肠切除术后出现慢性/复发性溃疡;(3)无全身炎症迹象;(4)无其他已知的小肠溃疡病因。SBCD 和 GITB 的诊断依据标准。临床特征、实验室参数、放射影像学检查、内窥镜检查(包括视频胶囊内窥镜检查 [VCE]、术中内窥镜检查)、组织病理学特征和治疗结果均被记录在案:在 48 例病例中,13 例(27%)被诊断为孤立性小肠和回盲肠狭窄,而 GITB 和 SBCD 分别占 41% 和 21%。常见表现为亚急性梗阻(46%)、不明显的消化道出血(38%)和蛋白丢失性肠病(38%)。与 SBCD 和 GITB 相比,CMUSE 患者的病程明显更长(P 结论:CMUSE 是一种重要的疾病,但却被低估了:CMUSE在儿童中很重要,但诊断不足。缺乏体征、正常的炎症指标和带有狭窄的特征性溃疡有助于将 CMUSE 与 GITB 和 SBCD 区分开来。
{"title":"Discrimination of pediatric cryptogenic multifocal ulcerous stenosing enteritis from small bowel Crohn's disease and gastrointestinal tuberculosis: A retrospective study (with videos).","authors":"Arghya Samanta, Moinak Sen Sarma, Sumit Kumar Singh, Anshu Srivastava, Ujjal Poddar, Ankur Mandelia, Vinita Agrawal, Surendra Kumar Yachha, Richa Lal","doi":"10.1007/s12664-024-01604-3","DOIUrl":"10.1007/s12664-024-01604-3","url":null,"abstract":"<p><strong>Introduction: </strong>Cryptogenic multifocal ulcerous stenosing enteritis (CMUSE) is a rare entity that mimics various inflammatory strictures of the small intestine. Pediatric literature is scarce. We analyzed the clinical, radiological, endoscopic and histopathological features of children with CMUSE that differentiate it from small bowel Crohn's disease (SBCD) and gastrointestinal tuberculosis (GITB).</p><p><strong>Methods: </strong>CMUSE was diagnosed by the following criteria: (1) unexplained small bowel strictures with superficial ulcers, (2) chronic/relapsing ulcers of small bowel after resection, (3) no signs of systemic inflammation, (4) absence of other known etiologies of small bowel ulcers. SBCD and GITB were diagnosed based on standard criteria. The clinical features, laboratory parameters, radioimaging, endoscopy (including video capsule endoscopy [VCE], intra-operative endoscopy), histopathological features and treatment outcome were noted.</p><p><strong>Results: </strong>Out of 48, CMUSE was diagnosed in 13 (27%) isolated small bowel and ileocecal strictures, while GITB and SBCD accounted for 41% and 21% cases, respectively. Common presentations were sub-acute obstruction (46%), obscure gastrointestinal bleeding (38%) and protein-losing enteropathy (38%). CMUSE patients had significantly longer disease duration compared to SBCD and GITB (p < 0.001). SBCD (90.0%) and GITB (85%) cases had elevated C-reactive protein (CRP), none with CMUSE had elevated CRP (p < 0.001). The disease was localized in jejunum (100%) and proximal ileum (56%) in CMUSE, ileocecal region (85%) in GITB, but evenly distributed in small intestine in SBCD. Endoscopy showed evenly placed, superficial, circumferential ulcers with strictures in CMUSE, deep linear ulcers in SBCD and circumferential ulcers in GITB. Upfront immunosuppression was given in four; three (75%) of them relapsed. Only surgery was done in three with one (25%) having relapse. Upfront surgery followed by immunosuppression was used in six, but all relapsed and two required repeat surgery.</p><p><strong>Conclusion: </strong>CMUSE is important but underdiagnosed in children. Lack of constitutional symptoms, normal inflammatory parameters and characteristic ulcers with strictures helped in differentiating CMUSE from GITB and SBCD.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma-A systematic review and meta-analysis. 肝细胞癌患者经颈静脉肝内门体分流术的有效性和安全性--系统回顾和荟萃分析。
IF 2 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-08-10 DOI: 10.1007/s12664-024-01646-7
Suprabhat Giri, Ankita Singh, Swati Das, Kateryna Strubchevska, Taraprasad Tripathy, Ranjan Kumar Patel, Marko Kozyk, Akash Roy

Background: Patients with hepatocellular carcinoma (HCC) and cirrhosis can present with features of severe portal hypertension, which can be worsened further by portal vein tumoral thrombosis (PVTT). Due to the technical difficulties and short survival of these patients, HCC was traditionally considered a relative contra-indication for transjugular intrahepatic portosystemic shunt (TIPS). However, there is an increasing body of evidence, mainly from China, supporting the use of TIPS in HCC. The present study aimed at analyzing the efficacy and safety of TIPS in patients with HCC.

Methods: From 2000 through May 2023, MEDLINE, Embase and Scopus were searched for studies analyzing the outcome of TIPS in HCC. Technical and clinical success, adverse events (AE) and mortality were the main outcomes assessed. With the use of a random effects model, the event rates were combined.

Results: Total 19 studies with 1498 patients were included in the final analysis. The pooled technical and clinical success rates with TIPS in HCC were 98.8% (98.0-99.7) and 94.1% (91.2-97.0), respectively. After TIPS, ascites was controlled in 89.2% (85.1-93.3) of the cases, while rebleeding was observed in 17.2% (9.4-25.0) of cases on follow-up. The pooled incidence of overall AE, serious AE and post-TIPS hepatic encephalopathy (HE) was 5.2% (2.5-7.9), 0.1% (0.0-0.4) and 25.1% (18.7-31.5), respectively. On follow-up, 11.9% (7.8-15.9) of the patients developed shunt dysfunction requiring re-intervention.

Conclusion: The present analysis supports the feasibility, safety and efficacy of TIPS in the management of portal hypertension in patients with HCC.

背景:肝细胞癌(HCC)和肝硬化患者会出现严重的门静脉高压症状,而门静脉肿瘤血栓形成(PVTT)会进一步加重病情。由于这些患者的技术难度大、存活时间短,传统上认为 HCC 是经颈静脉肝内门体分流术(TIPS)的相对禁忌症。然而,越来越多的证据(主要来自中国)支持在 HCC 患者中使用 TIPS。本研究旨在分析 TIPS 在 HCC 患者中的有效性和安全性:方法:从 2000 年到 2023 年 5 月,在 MEDLINE、Embase 和 Scopus 上检索分析 TIPS 治疗 HCC 效果的研究。评估的主要结果包括技术和临床成功率、不良事件(AE)和死亡率。采用随机效应模型对事件发生率进行了综合分析:最终分析共纳入了 19 项研究,1498 名患者。TIPS治疗HCC的技术和临床成功率分别为98.8%(98.0-99.7)和94.1%(91.2-97.0)。TIPS术后,89.2%(85.1-93.3)的病例腹水得到控制,而17.2%(9.4-25.0)的病例在随访中出现再出血。总体AE、严重AE和TIPS后肝性脑病(HE)的汇总发生率分别为5.2%(2.5-7.9)、0.1%(0.0-0.4)和25.1%(18.7-31.5)。在随访中,11.9%(7.8-15.9)的患者出现分流功能障碍,需要再次进行干预:本分析支持 TIPS 治疗 HCC 患者门静脉高压的可行性、安全性和有效性。
{"title":"Efficacy and safety of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma-A systematic review and meta-analysis.","authors":"Suprabhat Giri, Ankita Singh, Swati Das, Kateryna Strubchevska, Taraprasad Tripathy, Ranjan Kumar Patel, Marko Kozyk, Akash Roy","doi":"10.1007/s12664-024-01646-7","DOIUrl":"10.1007/s12664-024-01646-7","url":null,"abstract":"<p><strong>Background: </strong>Patients with hepatocellular carcinoma (HCC) and cirrhosis can present with features of severe portal hypertension, which can be worsened further by portal vein tumoral thrombosis (PVTT). Due to the technical difficulties and short survival of these patients, HCC was traditionally considered a relative contra-indication for transjugular intrahepatic portosystemic shunt (TIPS). However, there is an increasing body of evidence, mainly from China, supporting the use of TIPS in HCC. The present study aimed at analyzing the efficacy and safety of TIPS in patients with HCC.</p><p><strong>Methods: </strong>From 2000 through May 2023, MEDLINE, Embase and Scopus were searched for studies analyzing the outcome of TIPS in HCC. Technical and clinical success, adverse events (AE) and mortality were the main outcomes assessed. With the use of a random effects model, the event rates were combined.</p><p><strong>Results: </strong>Total 19 studies with 1498 patients were included in the final analysis. The pooled technical and clinical success rates with TIPS in HCC were 98.8% (98.0-99.7) and 94.1% (91.2-97.0), respectively. After TIPS, ascites was controlled in 89.2% (85.1-93.3) of the cases, while rebleeding was observed in 17.2% (9.4-25.0) of cases on follow-up. The pooled incidence of overall AE, serious AE and post-TIPS hepatic encephalopathy (HE) was 5.2% (2.5-7.9), 0.1% (0.0-0.4) and 25.1% (18.7-31.5), respectively. On follow-up, 11.9% (7.8-15.9) of the patients developed shunt dysfunction requiring re-intervention.</p><p><strong>Conclusion: </strong>The present analysis supports the feasibility, safety and efficacy of TIPS in the management of portal hypertension in patients with HCC.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141912458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mycobacterium avium complex small bowel disease mimicking Whipple's disease. 禽分枝杆菌复杂型小肠疾病,模仿惠普尔病。
IF 2 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-12-01 Epub Date: 2023-09-27 DOI: 10.1007/s12664-023-01461-6
Busara Songtanin, Atul Ratra, Dauod Arif, Kanak Das
{"title":"Mycobacterium avium complex small bowel disease mimicking Whipple's disease.","authors":"Busara Songtanin, Atul Ratra, Dauod Arif, Kanak Das","doi":"10.1007/s12664-023-01461-6","DOIUrl":"10.1007/s12664-023-01461-6","url":null,"abstract":"","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41110993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cold sub-mucosal injection versus traditional cold snare polypectomy for diminutive and small colorectal polyps: A systematic review and meta-analysis. 冷粘膜下注射与传统冷套法息肉切除术治疗微小结肠息肉:系统回顾和荟萃分析。
IF 2 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-07-02 DOI: 10.1007/s12664-024-01600-7
Yong-Cai Lv, Quan Dong, Yan-Hua Yao, Jing-Jing Lei

Background: The guidelines recommend conventional cold snare polypectomy (C-CSP) for diminutive and small colorectal polyps (≤ 10 mm). However, it remains unclear whether CSP with sub-mucosal injection (SI-CSP) achieves comparable efficacy to C-CSP for managing these lesions. This study compares SI-CSP with C-CSP for patients with diminutive and small colorectal polyps.

Methods: An electronic literature search was conducted to retrieve articles comparing resection outcomes between SI-CSP and C-CSP in diminutive and small colorectal polyps (registration number INPLASY2023100096). Our primary outcomes of interest were the complete resection rate (CRR), complications (namely immediate bleeding, delayed bleeding and perforation) and polypectomy time. Mean differences with 95% confidence intervals (CI) were employed for continuous variables, while odds ratios (OR) with 95% CI were calculated for categorical variables. Data was analyzed using a random effects model and the I2 test was utilized to assess heterogeneity.

Results: Eight studies involving 1470 patients with 2223 polyps were included in our analysis. The CRR was not significantly higher in the SI-CSP group, with an OR of 95% CI 0.50 (0.22, 1.15). The incidences of immediate bleeding (OR 95% CI 0.60 [0.26-1.40]) and delayed bleeding (OR 95% CI 0.88 [0.32-2.42]) did not differ significantly between the two groups. On average, the mean polypectomy time was 64.75 seconds shorter in the C-CSP group (95% CI, - 102.96 to - 26.53). Notably, no perforation events were reported in the included studies.

Conclusions: The use of SI-CSP was not superior to C-CSP in managing diminutive and small colorectal polyps and the procedure required significantly more time.

背景:指南推荐采用传统冷套法息肉切除术(C-CSP)治疗微小的结直肠息肉(≤ 10 毫米)。然而,在处理这些病变时,粘膜下注射冷息肉切除术(SI-CSP)是否能达到与 C-CSP 相媲美的疗效,目前仍不清楚。本研究比较了 SI-CSP 和 C-CSP 对微小结直肠息肉患者的治疗效果:我们进行了电子文献检索,以检索比较 SI-CSP 和 C-CSP 对微小和小型结直肠息肉切除效果的文章(注册号为 INPLASY2023100096)。我们关注的主要结果是完全切除率(CRR)、并发症(即即刻出血、延迟出血和穿孔)和息肉切除时间。连续变量采用平均差和 95% 置信区间 (CI),分类变量采用几率比 (OR) 和 95% 置信区间 (CI)。数据采用随机效应模型进行分析,并利用 I2 检验评估异质性:我们的分析共纳入了 8 项研究,涉及 1470 名患者和 2223 个息肉。SI-CSP组的CRR并无明显升高,OR值为95% CI 0.50 (0.22, 1.15)。两组间即刻出血(OR 95% CI 0.60 [0.26-1.40])和延迟出血(OR 95% CI 0.88 [0.32-2.42])的发生率无明显差异。平均而言,C-CSP 组的平均息肉切除时间缩短了 64.75 秒(95% CI,- 102.96 至 -26.53)。值得注意的是,纳入的研究均未报告穿孔事件:结论:SI-CSP 在治疗微小结直肠息肉方面并不优于 C-CSP,而且手术所需的时间明显更长。
{"title":"Cold sub-mucosal injection versus traditional cold snare polypectomy for diminutive and small colorectal polyps: A systematic review and meta-analysis.","authors":"Yong-Cai Lv, Quan Dong, Yan-Hua Yao, Jing-Jing Lei","doi":"10.1007/s12664-024-01600-7","DOIUrl":"10.1007/s12664-024-01600-7","url":null,"abstract":"<p><strong>Background: </strong>The guidelines recommend conventional cold snare polypectomy (C-CSP) for diminutive and small colorectal polyps (≤ 10 mm). However, it remains unclear whether CSP with sub-mucosal injection (SI-CSP) achieves comparable efficacy to C-CSP for managing these lesions. This study compares SI-CSP with C-CSP for patients with diminutive and small colorectal polyps.</p><p><strong>Methods: </strong>An electronic literature search was conducted to retrieve articles comparing resection outcomes between SI-CSP and C-CSP in diminutive and small colorectal polyps (registration number INPLASY2023100096). Our primary outcomes of interest were the complete resection rate (CRR), complications (namely immediate bleeding, delayed bleeding and perforation) and polypectomy time. Mean differences with 95% confidence intervals (CI) were employed for continuous variables, while odds ratios (OR) with 95% CI were calculated for categorical variables. Data was analyzed using a random effects model and the I<sup>2</sup> test was utilized to assess heterogeneity.</p><p><strong>Results: </strong>Eight studies involving 1470 patients with 2223 polyps were included in our analysis. The CRR was not significantly higher in the SI-CSP group, with an OR of 95% CI 0.50 (0.22, 1.15). The incidences of immediate bleeding (OR 95% CI 0.60 [0.26-1.40]) and delayed bleeding (OR 95% CI 0.88 [0.32-2.42]) did not differ significantly between the two groups. On average, the mean polypectomy time was 64.75 seconds shorter in the C-CSP group (95% CI, - 102.96 to - 26.53). Notably, no perforation events were reported in the included studies.</p><p><strong>Conclusions: </strong>The use of SI-CSP was not superior to C-CSP in managing diminutive and small colorectal polyps and the procedure required significantly more time.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinicopathological features and survival outcomes for gastric adenocarcinoma: Real-world single-center data. 胃腺癌的临床病理特征和生存结果:真实世界的单中心数据。
IF 2 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-12-01 Epub Date: 2023-11-10 DOI: 10.1007/s12664-023-01455-4
L Charles, Archana Elangovan, Yadav Nisha, Esha Jafa, Vikram Kate, Sandhiya Selvarajan, Smita Kayal, Rajesh Nachiappa Ganesh, Biswajit Dubashi, Prasanth Penumadu, Prasanth Ganesan

Introduction: Gastric cancer is the fifth most-common cancer and fourth common cause for cancer-related deaths globally. Surgery preceded or followed by chemotherapy or chemoradiotherapy is considered an optimal treatment for locally advanced gastric cancer. This study is a real-world data from a tertiary referral institute in southern India, in its experience with treating gastric adenocarcinoma over a period of four years with a minimum of two-year follow-up.

Methods: This was a retrospective analysis of data of patients with histologically proven gastric adenocarcinoma enrolled in the Department of Medical Oncology from 2015 to 2018. The demographic details, presentation, staging, treatment received and outcomes of patients with gastric adenocarcinoma were collected and analyzed in this study.

Results: Total 488 patients with gastric adenocarcinoma were included for the study. The stage-wise distribution of patients revealed early and locally advanced (45%) and metastatic (55%). The peritoneum and liver were the common sites of metastasis. The treatment distribution of these patients included perioperative chemotherapy followed by surgery (25 [5%]), surgery followed by adjuvant chemotherapy (65 [13%]), surgery alone (16 [3%]), perioperative chemotherapy alone (23 [4%]), palliative chemotherapy (274 [56%]) and supportive care (85 [17%]). The median overall survival for curative, palliative and supportive treatment was 23 (18-28), nine (7.6-10.4) and four (2.7-5.3) months, respectively. The two-year overall survival in the intention to treat population in the primary surgery (n = 81) and perioperative chemotherapy groups (n = 66) was 67.4% vs. 29.9% (p < 0.0001), respectively.

Conclusion: This study highlights the advanced nature of the presentation of gastric cancer patients and the poor rate of treatment completion. The median survival rates in curative patients remain to be dismally poor. The treatment sequence in curable gastric cancer of surgery followed by adjuvant chemotherapy vs. perioperative chemotherapy followed by surgery needs to be explored in our country.

简介:癌症是全球第五大最常见的癌症和第四大癌症相关死亡原因。在化疗或放化疗之前或之后进行手术被认为是局部晚期癌症的最佳治疗方法。这项研究是来自印度南部一家三级转诊研究所的真实世界数据,该研究所在四年内治疗胃腺癌的经验,至少有两年的随访。方法:这是对2015年至2018年在医学肿瘤科登记的经组织学证实的胃腺癌患者的数据进行的回顾性分析。本研究收集并分析了胃腺癌患者的人口统计学细节、表现、分期、接受的治疗和结果。结果:共有488例胃腺癌患者纳入研究。患者的分期分布显示早期和局部晚期(45%)以及转移性(55%)。腹膜和肝脏是常见的转移部位。这些患者的治疗分布包括围手术期化疗后手术(25[5])、手术后辅助化疗(65[13%])、单独手术(16[3%])、围手术期单独化疗(23[4])、姑息性化疗(274[56%])和支持性护理(85[17%])。治疗性、姑息性和支持性治疗的中位总生存期分别为23个月(18-28)、9个月(7.6-10.4)和4个月(2.7-5.3)。意向治疗人群在初次手术中的两年总生存率(n = 81)和围手术期化疗组(n = 66)分别为67.4%和29.9%(p 结论:本研究突出了癌症患者表现的先进性和较差的治疗完成率。治愈患者的中位生存率仍然很低。手术后辅助化疗与围手术期化疗后手术治疗癌症的治疗顺序有待我国进一步探索。
{"title":"Clinicopathological features and survival outcomes for gastric adenocarcinoma: Real-world single-center data.","authors":"L Charles, Archana Elangovan, Yadav Nisha, Esha Jafa, Vikram Kate, Sandhiya Selvarajan, Smita Kayal, Rajesh Nachiappa Ganesh, Biswajit Dubashi, Prasanth Penumadu, Prasanth Ganesan","doi":"10.1007/s12664-023-01455-4","DOIUrl":"10.1007/s12664-023-01455-4","url":null,"abstract":"<p><strong>Introduction: </strong>Gastric cancer is the fifth most-common cancer and fourth common cause for cancer-related deaths globally. Surgery preceded or followed by chemotherapy or chemoradiotherapy is considered an optimal treatment for locally advanced gastric cancer. This study is a real-world data from a tertiary referral institute in southern India, in its experience with treating gastric adenocarcinoma over a period of four years with a minimum of two-year follow-up.</p><p><strong>Methods: </strong>This was a retrospective analysis of data of patients with histologically proven gastric adenocarcinoma enrolled in the Department of Medical Oncology from 2015 to 2018. The demographic details, presentation, staging, treatment received and outcomes of patients with gastric adenocarcinoma were collected and analyzed in this study.</p><p><strong>Results: </strong>Total 488 patients with gastric adenocarcinoma were included for the study. The stage-wise distribution of patients revealed early and locally advanced (45%) and metastatic (55%). The peritoneum and liver were the common sites of metastasis. The treatment distribution of these patients included perioperative chemotherapy followed by surgery (25 [5%]), surgery followed by adjuvant chemotherapy (65 [13%]), surgery alone (16 [3%]), perioperative chemotherapy alone (23 [4%]), palliative chemotherapy (274 [56%]) and supportive care (85 [17%]). The median overall survival for curative, palliative and supportive treatment was 23 (18-28), nine (7.6-10.4) and four (2.7-5.3) months, respectively. The two-year overall survival in the intention to treat population in the primary surgery (n = 81) and perioperative chemotherapy groups (n = 66) was 67.4% vs. 29.9% (p < 0.0001), respectively.</p><p><strong>Conclusion: </strong>This study highlights the advanced nature of the presentation of gastric cancer patients and the poor rate of treatment completion. The median survival rates in curative patients remain to be dismally poor. The treatment sequence in curable gastric cancer of surgery followed by adjuvant chemotherapy vs. perioperative chemotherapy followed by surgery needs to be explored in our country.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72014174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rome III and IV criteria are less discordant to diagnose irritable bowel syndrome in clinic patients than in community subjects. 在诊断肠易激综合征时,罗马III和罗马IV标准在临床患者中的不一致性要小于在社区受试者中的不一致性。
IF 2 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-29 DOI: 10.1007/s12664-024-01611-4
Uday C Ghoshal, Uzma Mustafa, Vipin Kumar Pandey

Background: Though Rome IV criteria for irritable bowel syndrome (IBS) are less sensitive; they select Rome III patients with greater severity and consultation behavior. Since severity of IBS may determine consultation behavior, we compared Rome III and IV criteria in clinic patients and compared with earlier published data from Indian community hypothesizing that the diagnostic discordance between these criteria would be less in clinic than in community.

Methods: Tertiary clinic patients were screened for IBS using Hindi translated-validated Rome III and IV questionnaires; IBS symptom severity scores (IBS-SSS) was also assessed. Diagnostic discordance between Rome III and IV criteria for IBS was compared with earlier published Indian community data.

Results: Of 110 clinic patients with functional gastrointestinal disorders, 72 met IBS criteria (47 [42.7%], 22 [20%] and three [2.7%] both Rome III and IV criteria, Rome III criteria only and Rome IV criteria only, respectively). In contrast, of 40 IBS subjects from Indian community published earlier, nine (22.5%), 28 (70%) and three (7.5%) fulfilled both Rome III and IV, Rome III only, Rome IV only criteria, respectively. Clinic patients with IBS fulfilling both Rome III and IV criteria or Rome IV criteria had higher IBS-SSS than those fulfilling Rome III criteria only (295.3 ± 80.7 vs. 205.6 ± 65.7; p < 0.00001). This difference was primarily related to pain severity and number of days with pain.

Conclusion: Discordance between Rome IV and Rome III criteria in tertiary care clinic patients is less than in community subjects with IBS in India.

背景:虽然肠易激综合征(IBS)的罗马 IV 标准灵敏度较低;但它们选择的罗马 III 病人的严重程度更高,就诊行为也更多。由于肠易激综合征的严重程度可能决定就诊行为,我们比较了诊所患者的罗马 III 和罗马 IV 标准,并与印度社区早先发表的数据进行了比较,假设这些标准之间的诊断不一致在诊所会比在社区少:方法: 使用经印地语翻译验证的罗马III和罗马IV调查问卷对三级诊所患者进行肠易激综合征筛查;同时评估肠易激综合征症状严重程度评分(IBS-SSS)。将 IBS 的罗马 III 和 IV 标准之间的诊断不一致性与早先公布的印度社区数据进行了比较:结果:在 110 名患有功能性胃肠功能紊乱的门诊患者中,72 人符合 IBS 标准(分别有 47 人[42.7%]、22 人[20%]和 3 人[2.7%]同时符合罗马 III 和 IV 标准、仅符合罗马 III 标准和仅符合罗马 IV 标准)。相比之下,在早前发表的 40 名印度社区 IBS 患者中,分别有 9 人(22.5%)、28 人(70%)和 3 人(7.5%)同时符合罗马 III 和 IV 标准、仅符合罗马 III 标准和仅符合罗马 IV 标准。同时符合罗马Ⅲ和罗马Ⅳ标准或罗马Ⅳ标准的肠易激综合征患者的 IBS-SSS 值高于仅符合罗马Ⅲ标准的患者(295.3 ± 80.7 vs. 205.6 ± 65.7;P 结论:罗马Ⅳ标准和罗马Ⅲ标准不一致:在印度,三级医疗诊所患者中罗马 IV 和罗马 III 标准的不一致性低于社区 IBS 患者。
{"title":"Rome III and IV criteria are less discordant to diagnose irritable bowel syndrome in clinic patients than in community subjects.","authors":"Uday C Ghoshal, Uzma Mustafa, Vipin Kumar Pandey","doi":"10.1007/s12664-024-01611-4","DOIUrl":"10.1007/s12664-024-01611-4","url":null,"abstract":"<p><strong>Background: </strong>Though Rome IV criteria for irritable bowel syndrome (IBS) are less sensitive; they select Rome III patients with greater severity and consultation behavior. Since severity of IBS may determine consultation behavior, we compared Rome III and IV criteria in clinic patients and compared with earlier published data from Indian community hypothesizing that the diagnostic discordance between these criteria would be less in clinic than in community.</p><p><strong>Methods: </strong>Tertiary clinic patients were screened for IBS using Hindi translated-validated Rome III and IV questionnaires; IBS symptom severity scores (IBS-SSS) was also assessed. Diagnostic discordance between Rome III and IV criteria for IBS was compared with earlier published Indian community data.</p><p><strong>Results: </strong>Of 110 clinic patients with functional gastrointestinal disorders, 72 met IBS criteria (47 [42.7%], 22 [20%] and three [2.7%] both Rome III and IV criteria, Rome III criteria only and Rome IV criteria only, respectively). In contrast, of 40 IBS subjects from Indian community published earlier, nine (22.5%), 28 (70%) and three (7.5%) fulfilled both Rome III and IV, Rome III only, Rome IV only criteria, respectively. Clinic patients with IBS fulfilling both Rome III and IV criteria or Rome IV criteria had higher IBS-SSS than those fulfilling Rome III criteria only (295.3 ± 80.7 vs. 205.6 ± 65.7; p < 0.00001). This difference was primarily related to pain severity and number of days with pain.</p><p><strong>Conclusion: </strong>Discordance between Rome IV and Rome III criteria in tertiary care clinic patients is less than in community subjects with IBS in India.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141476499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Indian Journal of Gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1